Cargando…

METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS

The genetic contribution of rare pathogenic germline variation in cancer patients without a family history remains unclear. We sought to characterize the prevalence, spectrum, and clinical significance of pathogenic germline variation in cancer predisposition genes (CPGs) in pediatric brain tumor pa...

Descripción completa

Detalles Bibliográficos
Autores principales: McQuaid, Shelly W, Kaufman, Rebecca, Corbett, Ryan J, Vaksman, Zalman, Bornhorst, Miriam, Brown, Miguel A, Guo, Yiran S, Zhu, Yuankun, Heath, Allison P, Storm, Phillip B, Resnick, Adam C, Waanders, Angela J, Cole, Kristina A, Rokita, Jo Lynne, Macfarland, Suzanne, Diskin, Sharon J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260081/
http://dx.doi.org/10.1093/neuonc/noad073.126
_version_ 1785057784165826560
author McQuaid, Shelly W
Kaufman, Rebecca
Corbett, Ryan J
Vaksman, Zalman
Bornhorst, Miriam
Brown, Miguel A
Guo, Yiran S
Zhu, Yuankun
Heath, Allison P
Storm, Phillip B
Resnick, Adam C
Waanders, Angela J
Cole, Kristina A
Rokita, Jo Lynne
Macfarland, Suzanne
Diskin, Sharon J
author_facet McQuaid, Shelly W
Kaufman, Rebecca
Corbett, Ryan J
Vaksman, Zalman
Bornhorst, Miriam
Brown, Miguel A
Guo, Yiran S
Zhu, Yuankun
Heath, Allison P
Storm, Phillip B
Resnick, Adam C
Waanders, Angela J
Cole, Kristina A
Rokita, Jo Lynne
Macfarland, Suzanne
Diskin, Sharon J
author_sort McQuaid, Shelly W
collection PubMed
description The genetic contribution of rare pathogenic germline variation in cancer patients without a family history remains unclear. We sought to characterize the prevalence, spectrum, and clinical significance of pathogenic germline variation in cancer predisposition genes (CPGs) in pediatric brain tumor patients. Paired tumor and normal whole genome or exome sequencing was performed for 838 patients in the Pediatric Brain Tumor Atlas (PBTA). Rare variants in 196 CPGs were annotated as pathogenic (P) or likely pathogenic (LP) in an automated manner consistent with American College of Medical Genetics criteria and reviewed by an interdisciplinary panel. To assess enrichment, the frequency of CPG P-LP variants in cases was compared to the gnomAD v3.1 cancer-free control cohort (n=74,023). Second hit, mutational signature, and gene set enrichment analyses (GSEA) were performed on matched tumor sequencing to characterize differences in patients with and without germline P-LP variants in DNA repair genes. We observed 178 germline CPG P-LP variants in 163 PBTA patients (19.5%). CPG P-LP variants were most prevalent among Neurofibroma plexiform patients (64.3%), and NF1 and TSC2 harbored the most significant P-LP variant burden compared to controls (OR=69.5, p=2.4E-23, CI=34.6-137 and OR=357, p=1.1E-14, CI=71-3669, respectively). DNA repair gene P-LP variants were enriched in cases compared to controls (OR=4.4, p=8.3E-30). Patients harboring mismatch repair (MMR) gene P-LP variants exhibited significantly higher tumor-associated MMR-deficiency mutational signature exposures (p<0.05) and DNA repair GSEA scores relative to other patients (p=0.04). Second hit SNVs in tumors were identified in four patients with P-LP germline variants in NF1 (n=2), APC (n=1), and SUFU (n=1). Germline P-LP variants are enriched in PBTA patients, and DNA repair variants are predictive of repair-deficiency signatures in tumor samples. Our work emphasizes the need for germline sequencing to inform patient care.
format Online
Article
Text
id pubmed-10260081
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102600812023-06-13 METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS McQuaid, Shelly W Kaufman, Rebecca Corbett, Ryan J Vaksman, Zalman Bornhorst, Miriam Brown, Miguel A Guo, Yiran S Zhu, Yuankun Heath, Allison P Storm, Phillip B Resnick, Adam C Waanders, Angela J Cole, Kristina A Rokita, Jo Lynne Macfarland, Suzanne Diskin, Sharon J Neuro Oncol Final Category: Genomics/Epigenomics/Metabolomics - METB The genetic contribution of rare pathogenic germline variation in cancer patients without a family history remains unclear. We sought to characterize the prevalence, spectrum, and clinical significance of pathogenic germline variation in cancer predisposition genes (CPGs) in pediatric brain tumor patients. Paired tumor and normal whole genome or exome sequencing was performed for 838 patients in the Pediatric Brain Tumor Atlas (PBTA). Rare variants in 196 CPGs were annotated as pathogenic (P) or likely pathogenic (LP) in an automated manner consistent with American College of Medical Genetics criteria and reviewed by an interdisciplinary panel. To assess enrichment, the frequency of CPG P-LP variants in cases was compared to the gnomAD v3.1 cancer-free control cohort (n=74,023). Second hit, mutational signature, and gene set enrichment analyses (GSEA) were performed on matched tumor sequencing to characterize differences in patients with and without germline P-LP variants in DNA repair genes. We observed 178 germline CPG P-LP variants in 163 PBTA patients (19.5%). CPG P-LP variants were most prevalent among Neurofibroma plexiform patients (64.3%), and NF1 and TSC2 harbored the most significant P-LP variant burden compared to controls (OR=69.5, p=2.4E-23, CI=34.6-137 and OR=357, p=1.1E-14, CI=71-3669, respectively). DNA repair gene P-LP variants were enriched in cases compared to controls (OR=4.4, p=8.3E-30). Patients harboring mismatch repair (MMR) gene P-LP variants exhibited significantly higher tumor-associated MMR-deficiency mutational signature exposures (p<0.05) and DNA repair GSEA scores relative to other patients (p=0.04). Second hit SNVs in tumors were identified in four patients with P-LP germline variants in NF1 (n=2), APC (n=1), and SUFU (n=1). Germline P-LP variants are enriched in PBTA patients, and DNA repair variants are predictive of repair-deficiency signatures in tumor samples. Our work emphasizes the need for germline sequencing to inform patient care. Oxford University Press 2023-06-12 /pmc/articles/PMC10260081/ http://dx.doi.org/10.1093/neuonc/noad073.126 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Final Category: Genomics/Epigenomics/Metabolomics - METB
McQuaid, Shelly W
Kaufman, Rebecca
Corbett, Ryan J
Vaksman, Zalman
Bornhorst, Miriam
Brown, Miguel A
Guo, Yiran S
Zhu, Yuankun
Heath, Allison P
Storm, Phillip B
Resnick, Adam C
Waanders, Angela J
Cole, Kristina A
Rokita, Jo Lynne
Macfarland, Suzanne
Diskin, Sharon J
METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS
title METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS
title_full METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS
title_fullStr METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS
title_full_unstemmed METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS
title_short METB-09. GERMLINE PATHOGENIC VARIANTS IN 838 PEDIATRIC BRAIN TUMOR PATIENTS
title_sort metb-09. germline pathogenic variants in 838 pediatric brain tumor patients
topic Final Category: Genomics/Epigenomics/Metabolomics - METB
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260081/
http://dx.doi.org/10.1093/neuonc/noad073.126
work_keys_str_mv AT mcquaidshellyw metb09germlinepathogenicvariantsin838pediatricbraintumorpatients
AT kaufmanrebecca metb09germlinepathogenicvariantsin838pediatricbraintumorpatients
AT corbettryanj metb09germlinepathogenicvariantsin838pediatricbraintumorpatients
AT vaksmanzalman metb09germlinepathogenicvariantsin838pediatricbraintumorpatients
AT bornhorstmiriam metb09germlinepathogenicvariantsin838pediatricbraintumorpatients
AT brownmiguela metb09germlinepathogenicvariantsin838pediatricbraintumorpatients
AT guoyirans metb09germlinepathogenicvariantsin838pediatricbraintumorpatients
AT zhuyuankun metb09germlinepathogenicvariantsin838pediatricbraintumorpatients
AT heathallisonp metb09germlinepathogenicvariantsin838pediatricbraintumorpatients
AT stormphillipb metb09germlinepathogenicvariantsin838pediatricbraintumorpatients
AT resnickadamc metb09germlinepathogenicvariantsin838pediatricbraintumorpatients
AT waandersangelaj metb09germlinepathogenicvariantsin838pediatricbraintumorpatients
AT colekristinaa metb09germlinepathogenicvariantsin838pediatricbraintumorpatients
AT rokitajolynne metb09germlinepathogenicvariantsin838pediatricbraintumorpatients
AT macfarlandsuzanne metb09germlinepathogenicvariantsin838pediatricbraintumorpatients
AT diskinsharonj metb09germlinepathogenicvariantsin838pediatricbraintumorpatients